Alumis (ALMS) 2025 Conference June 04, 2025 03:10 PM ET Speaker0 Good evening, everyone, and welcome to the Global Jeffries Healthcare Conference. My name is Camden with the Jeffries Healthcare team, and it's my pleasure to introduce Martin Babler, CEO of Illumis. Speaker1 Thank you very much, and welcome to our presentation this afternoon. And I want to thank Jefferies for actually offering us to present our company here and participate in some one on one meetings. I'm going to give you a brief overview of ...

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the Jefferies Global Healthcare Conference on June 4, 2025 at 3:10 p.m. ET. A live webcast will be available on the Alumis website in the "Investors" section under the “Events” page. A replay of the c ...

Core Insights - Alumis Inc. has completed patient enrollment in its pivotal Phase 3 ONWARD clinical program for ESK-001, targeting moderate-to-severe plaque psoriasis, with over 1,700 patients enrolled [2][4] - Topline results are expected to be reported in early Q1 2026, indicating progress towards providing new treatment options for patients [1][2] - ESK-001 is a next-generation oral TYK2 inhibitor designed to address immune dysregulation in various diseases, including plaque psoriasis [3][7] Clinical Program Details - The ONWARD clinical program consists of two parallel global Phase 3 trials, ONWARD1 and ONWARD2, each lasting 24 weeks and designed to evaluate the efficacy and safety of ESK-001 [4][5] - Patients are randomized in a 2:1:1 ratio to receive either ESK-001 40 mg twice daily, placebo, or apremilast, with co-primary endpoints focusing on the Psoriasis Area and Severity Index (PASI 75) and sPGA score [4][5] - An optional long-term extension trial, ONWARD3, is ongoing to assess the durability and long-term safety of ESK-001 for patients completing Week 24 [5] Product Profile - ESK-001 is characterized as a highly selective oral TYK2 inhibitor, aiming to minimize off-target effects while providing effective treatment for immune-mediated diseases [3][7] - The drug's development is supported by positive data from the Phase 2 STRIDE clinical trial and ongoing long-term open-label extensions [5] Broader Development Pipeline - Alumis is also exploring ESK-001's potential in other immune-mediated conditions, including a Phase 2b trial for systemic lupus erythematosus [6][7] - The company is developing a once-daily modified-release formulation of ESK-001 to enhance patient convenience compared to the current twice-daily regimen [5]

Company Overview - Alumis Inc. has completed its merger with ACELYRIN, Inc., establishing itself as a leading clinical-stage biopharma company with a differentiated portfolio of therapies and a strong balance sheet [1][3] - Each ACELYRIN stockholder will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned, with ACELYRIN common stock ceasing to trade on NASDAQ [2] Financial Position - The merger significantly strengthens Alumis' balance sheet, allowing for the advancement of its late-stage portfolio and the development of transformative therapies for patients [3] - Alumis now has a cash runway that extends into 2027, supporting multiple planned key data readouts [3] Product Pipeline - Alumis is developing next-generation targeted therapies for immune-mediated diseases, including oral tyrosine kinase 2 inhibitors such as ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [5] - The pipeline also includes lonigutamab, an anti–insulin-like growth factor 1 receptor therapy for thyroid eye disease, along with several preclinical programs identified through a precision approach [5] Advisory Team - Morgan Stanley & Co. LLC served as the financial advisor to Alumis, while Cooley LLP acted as its legal counsel [4] - Guggenheim Securities, LLC served as the financial advisor to ACELYRIN, with Fenwick & West LLP and Paul Hastings LLP providing legal counsel [4]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-42143 Alumis Inc. (Exact name of registrant as specified in its charter) Delaware 86-1771129 (State or other ...

First Quarter 2025 and Recent Highlights ● Updates related to merger agreement with ACELYRIN, Inc. (ACELYRIN), enabling enhanced value creation opportunities for each company's respective stockholders and positioning transaction for successful close in the second quarter of 2025 ● On May 13, 2025, Alumis stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN at its Special Meeting of Stockholders. ● In April 2025, Alumis and ACELYRIN agreed to ...

SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones. “We’re seeing strong momentum across our development programs, with our team continui ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (Nasdaq: SLRN) at its Special Meeting of Stockholders. Martin Babler, P ...

ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehen ...

With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market. Three biopharmaceuticals firms—Alumis N ...